Guizhou Sanli Pharmaceutical Co.Ltd(603439) (603439) announced on February 6 that it plans to become the bankruptcy reorganization investor of dechangxiang and make a one-time investment of 232 million yuan to obtain 95% equity of dechangxiang. According to the analysis of the company, “dechangxiang” brand is a century old brand with great influence. Its predecessor is Guiyang traditional Chinese medicine factory, with many high-quality drug approvals. The company’s investment in dechangxiang is based on expanding product types, solving the risk of relative concentration of the company’s products and improving the company’s industry competitiveness, which is of positive significance to the company’s market competition and development ability.
© China Stock Market News